Harmony Biosciences (NASDAQ:HRMY) said that data from a phase 2 study indicated that its myotonic dystrophy candidate pitolisant reduced excessive daytime sleepiness and fatigue compared to placebo. ...
Source LinkHarmony Biosciences (NASDAQ:HRMY) said that data from a phase 2 study indicated that its myotonic dystrophy candidate pitolisant reduced excessive daytime sleepiness and fatigue compared to placebo. ...
Source Link
Comments